Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies

Angiogenesis is a hallmark of cancer development. This study sought to determine the recommended dose of aflibercept, a recombinant fusion protein targeting VEGF-A, VEGF-B and placental growth factor (PlGF), combined with docetaxel in Japanese patients with advanced solid malignancies. This phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunakawa, Yu, Takahashi, Keishiro, Kawaguchi, Osamu, Yamamoto, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395466/
https://www.ncbi.nlm.nih.gov/pubmed/35771301
http://dx.doi.org/10.1007/s10637-022-01267-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395466/
https://www.ncbi.nlm.nih.gov/pubmed/35771301
http://dx.doi.org/10.1007/s10637-022-01267-x

Ejemplares similares